DS
SNDX icon

David Shaw’s Syndax Pharmaceuticals SNDX Stock Holding History

David Shaw’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.1M Sell
1,239,954
-361,942
-23% -$7.53M 0.01% 1098
2026
Q1 		$37.4M Buy
1,601,896
+382,287
+31% +$8.31M 0.02% 802
2025
Q4 		$25.6M Buy
1,219,609
+142,024
+13% +$2.48M 0.01% 1088
2025
Q3 		$16.6M Buy
1,077,585
+433,043
+67% +$5.67M 0.01% 1311
2025
Q2 		$6.04M Sell
644,542
-143,045
-18% -$1.57M ﹤0.01% 1884
2025
Q1 		$9.68M Buy
787,587
+603,470
+328% +$8.51M 0.01% 1429
2024
Q4 		$2.43M Sell
184,117
-168,241
-48% -$2.88M ﹤0.01% 2570
2024
Q3 		$6.78M Buy
352,358
+205,715
+140% +$4.25M 0.01% 1707
2024
Q2 		$3.01M Buy
146,643
+138,119
+1,620% +$2.89M ﹤0.01% 2259
2024
Q1 		$203K Sell
8,524
-33,441
-80% -$746K ﹤0.01% 3919
2023
Q4 		$907K Sell
41,965
-106,607
-72% -$1.64M ﹤0.01% 3198
2023
Q3 		$2.16M Sell
148,572
-24,447
-14% -$462K ﹤0.01% 2508
2023
Q2 		$3.62M Buy
173,019
+33,952
+24% +$707K ﹤0.01% 2119
2023
Q1 		$2.94M Sell
139,067
-21,368
-13% -$532K ﹤0.01% 2392
2022
Q4 		$4.08M Buy
160,435
+32,407
+25% +$756K ﹤0.01% 2283
2022
Q3 		$3.08M Buy
+128,028
New +$2.87M ﹤0.01% 2619
2022
Q1 		– Sell
-123,303
Closed -$2.7M – 5906
2021
Q4 		$2.7M Sell
123,303
-213,843
-63% -$3.95M ﹤0.01% 3075
2021
Q3 		$6.44M Sell
337,146
-73,321
-18% -$1.22M 0.01% 1876
2021
Q2 		$7.05M Sell
410,467
-163,471
-28% -$2.99M 0.01% 1770
2021
Q1 		$12.8M Sell
573,938
-81,069
-12% -$1.83M 0.01% 1200
2020
Q4 		$14.6M Buy
655,007
+405,580
+163% +$8.41M 0.01% 1133
2020
Q3 		$3.68M Buy
249,427
+148,836
+148% +$2.27M ﹤0.01% 1922
2020
Q2 		$1.49M Buy
100,591
+23,018
+30% +$351K ﹤0.01% 2637
2020
Q1 		$851K Buy
77,573
+13,840
+22% +$130K ﹤0.01% 2867
2019
Q4 		$559K Buy
+63,733
New +$468K ﹤0.01% 3337
2018
Q1 		– Sell
-23,063
Closed -$202K – 3759
2017
Q4 		$202K Buy
23,063
+7,433
+48% +$73.6K ﹤0.01% 3430
2017
Q3 		$183K Buy
+15,630
New +$192K ﹤0.01% 3317

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's SNDX Position: Q2 2026 in Review

David Shaw reduced its Syndax Pharmaceuticals (SNDX) stake by 23% in Q2 2026, selling an estimated $7.53M and leaving 1,239,954 shares worth $27.1M. The position accounts for 0.01% of the portfolio, ranked #1098.

David Shaw first reported a position in SNDX in Q3 2017 and has held it in 27 quarters since. The position peaked at $37.4M in Q1 2026. 241 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • David Shaw held 1,239,954 shares of Syndax Pharmaceuticals worth $27.1M as of Q2 2026.
  • David Shaw sold 361,942 Syndax Pharmaceuticals shares in Q2 2026, an estimated $7.53M.
  • Syndax Pharmaceuticals made up 0.01% of David Shaw's portfolio in Q2 2026, its #1098 holding.
  • David Shaw first reported a position in Syndax Pharmaceuticals in Q3 2017 and has held it in 27 quarters since.
  • David Shaw's Syndax Pharmaceuticals position peaked at $37.4M in Q1 2026.
  • 241 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.